Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06AEO
|
||||
| Former ID |
DAP000906
|
||||
| Drug Name |
Cyproterone
|
||||
| Synonyms |
Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Prostate cancer [ICD9: 185; ICD10:C61] | Approved | [550706] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Schering-Plough
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H27ClO3
|
||||
| Canonical SMILES |
CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)O
|
||||
| InChI |
1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12?,13-,14?,15?,16+,20?,21?,22+/m1/s1
|
||||
| InChIKey |
DUSHUSLJJMDGTE-LXMMIWJPSA-N
|
||||
| CAS Number |
CAS 2098-66-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| ChEBI ID |
ChEBI:50742
|
||||
| SuperDrug ATC ID |
G03HA01
|
||||
| SuperDrug CAS ID |
cas=002098660
|
||||
| Target and Pathway | |||||
| Target(s) | Androgen receptor | Target Info | Antagonist | [537365] | |
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Coregulation of Androgen receptor activity | |||||
| Regulation of Androgen receptor activity | |||||
| Nongenotropic Androgen signaling | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| FOXA1 transcription factor network | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.